146 related articles for article (PubMed ID: 16996111)
1. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.
Günthert AR; Ackermann S; Beckmann MW; Camara O; Kiesel L; Rensing K; Schröder W; Steiner E; Emons G;
Gynecol Oncol; 2007 Jan; 104(1):86-90. PubMed ID: 16996111
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Pearl ML; Johnston CM; McMeekin DS
Gynecol Obstet Invest; 2007; 64(4):193-8. PubMed ID: 17664880
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Katsumata N; Noda K; Nozawa S; Kitagawa R; Nishimura R; Yamaguchi S; Aoki D; Susumu N; Kuramoto H; Jobo T; Ueki K; Ueki M; Kohno I; Fujiwara K; Sohda Y; Eguchi F
Br J Cancer; 2005 Oct; 93(9):999-1004. PubMed ID: 16234823
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
7. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
Ji JH; ; Yun T; Kim SB; Kang JH; Park JC; Cho IS; Sohn CH; Heo DS; Jang JS; Shin SW; Hwang DW; Sun JM; Park K; Ahn MJ
Eur J Cancer; 2012 Nov; 48(17):3198-204. PubMed ID: 22795584
[TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group.
Garcia AA; Blessing JA; Nolte S; Mannel RS;
Gynecol Oncol; 2008 Oct; 111(1):22-6. PubMed ID: 18675446
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Lim JY; Cho JY; Paik YH; Lee DK; Lee SI; Park HJ; Lee SJ; Lee KS; Yoon DS; Choi SH
Oncology; 2007; 73(1-2):2-8. PubMed ID: 18332648
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
13. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
Traina TA; Sabbatini P; Aghajanian C; Dupont J
Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
Wang B; Zhang W; Hong X; Guo Y; Li J
Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
[TBL] [Abstract][Full Text] [Related]
18. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
19. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]